Argos Therapeutics Inc. (ARGS) Shares Down 8.9%
Argos Therapeutics Inc. (NASDAQ:ARGS)’s share price traded down 8.9% during mid-day trading on Tuesday . The stock traded as low as $5.75 and last traded at $5.87, with a volume of 138,363 shares trading hands. The stock had previously closed at $6.44.
Several equities analysts have recently issued reports on the company. FBR & Co reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, May 14th. JPMorgan Chase & Co. reduced their target price on Argos Therapeutics from $17.00 to $12.00 and set a “market outperform” rating on the stock in a research note on Wednesday, March 9th. Needham & Company LLC reissued a “buy” rating on shares of Argos Therapeutics in a research note on Saturday, April 23rd. Zacks Investment Research cut Argos Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Finally, Roth Capital boosted their target price on Argos Therapeutics from $11.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 19th. Eight investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $11.84.
The company’s market cap is $152.24 million. The company has a 50 day moving average of $6.10 and a 200-day moving average of $5.23.
Argos Therapeutics (NASDAQ:ARGS) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.01. On average, analysts anticipate that Argos Therapeutics Inc. will post ($1.74) EPS for the current fiscal year.
Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.